Fig. 2. TT-301 treatment improves vestibular and cognitive deficits associated with traumatic brain injury (TBI). Treatment with TT-301 was associated with durable improvements in vestibulomotor and neurocognitive function as compared with vehicle-treated mice, as demonstrated by longer Rotorod latencies (A ) during the first 7 days post-TBI and shorter Morris water maze latencies (B ) 4 weeks post-TBI, despite similar swimming speeds. *P < 0.05 as assessed by ANOVA. Mortality between the groups was not significant [TT-301 (1 mg/kg) vs. vehicle: 8.3% (1 of 12) vs. 8.3% (1 of 12)].